Chinese Scientists Develop RNA Vaccine Against Pancreatic Cancer
The drug successfully passed the first phase of trials in mice and primates, completely suppressing metastases.
Topic: RNA vaccine against pancreatic cancer — the end of the chemotherapy era or another bubble?
I have been analyzing the therapeutic vaccine market since 2019, and the news that a Chinese team from Sir Run Run Shaw Hospital, affiliated with Zhejiang University, reported a 100% immune response to the personalized mRNA vaccine iNeo-Vac-R01 is not just a breakthrough. It is a moment of truth for all of oncology. The data were presented at the November 2025 conference of the Society for Immunotherapy of Cancer (SITC), and while mainstream media regurgitate press releases, insiders are already counting the losses of chemotherapy drug manufacturers.
But let's set aside emotions. What you see in headlines like "complete suppression of metastases" is a cliché. The real drama revolves around overall survival (OS) and progression-free survival (PFS) numbers, and how these numbers will bury the old standard of care. In this text, I will break down what actually lies behind mRNA vaccines for treating PDAC (pancreatic ductal adenocarcinoma) and why the largest pharma giants have been buying up neoantigen startups for the past year.
[The Gist]: What's Really Happening
We are witnessing a paradigm shift: from a toxic "silver bullet" to biological programming of the immune system. Pancreatic cancer has historically been considered a "cold" tumor — the immune system simply doesn't see it due to dense stroma and an immunosuppressive microenvironment. Traditional chemotherapy (e.g., the mFOLFIRINOX regimen) yields a median PFS of only about 6.4 months. A terrifying number. However, the new vaccines — in particular iNeo-Vac-R01 and its Western counterpart autogene cevumeran (BNT122 from BioNTech/Genentech) — don't just "teach" the immune system; they literally rewrite the patient's T-cell repertoire.
The point is that "complete suppression" in mice and primates is a pretty lab picture. In humans, it's more complicated, but the numbers published in the Journal for ImmunoTherapy of Cancer on November 7, 2025, shock even us skeptics. In patients with advanced disease, who previously were given 3-5 months, the median overall survival (mOS) with the vaccine combined with chemotherapy reached 19.7 months. Let that sink in: 19.7 versus 11.1 in the historical control of PRODIGE 4. This is no longer an "improvement"; it's a blowout.
But why did this happen now? Because developers stopped guessing. The modern protocol involves sequencing the patient's tumor after resection, a complex AI algorithm to predict neoantigens (mutations unique to that individual's cancer cells), and manufacturing RNA in lipid nanoparticles within 6-9 weeks. The Chinese iNeo-Vac-R01 protocol showed that out of 153 tested neoantigens, 93 (60.8%) elicited a response. That's hitting the bullseye at the molecular level.
At the same time, we inside the industry see the flip side. The effect is achieved only under ideal conditions. In the MSK Cancer Center (Memorial Sloan Kettering) study, 16 patients were enrolled, and a detectable T-cell response occurred in only 50%. The other 8 simply did not respond to the vaccine — their tumors were smarter. So the phrase "completely suppressing metastases" is marketing applied to the group of responders. Nevertheless, in that group, there were no recurrences (RFS not reached) versus 13.4 months in non-responders. A fat period in the debate "does it work or not."
Timeline and Context
The roots of the technology go back to pre-COVID 2019, when BioNTech conceived the iNeST platform (individualized Neoantigen Specific Immunotherapy). The pandemic became a "baptism by fire" for mRNA vaccines — companies fine-tuned logistics and production of lipid nanoparticles to industrial scale. The key moment came in 2023, when the first global randomized research project for PDAC started. And in February 2025, three-year follow-up data from MSK patients were released: vaccine-induced T cells lived in the body for years, and modeling showed that about 20% of clones would persist for decades.
As for the Chinese development iNeo-Vac-R01 (registration number NCT06026800), it ran a parallel course but with an important difference: they tested the vaccine specifically in the first-line setting, not adjuvant as the Americans did. Final data cut as of August 31, 2025, showed: in 10 patients with metastases (60% had liver involvement), median PFS was 14.9 months. The context here is geopolitical: while the US and Europe figure out how to make personalized medicine cheaper (which is prohibitively expensive), China packages the same technology into a cheaper sequencing protocol and hits the market with a flood of clinical data.
It's important to understand the timeline of clinical implementation. In fall 2025, articles in Nature and Nature Medicine described amphiphilic vaccines (ELI-002, targeting mutant KRAS) — they showed an 84% immune response but a narrower focus. By December 2025, it became clear that hybrid protocols (amphiphile prime + mRNA boost) would be the standard. What is now presented as "news of the week" was actually predetermined back in August 2025 at closed ASCO sessions (American Society of Clinical Oncology).
Who Wins and Who Loses
The number one beneficiary is BioNTech. Their partnership with Genentech on the vaccine autogene cevumeran (BNT122) has driven the company's stock up 34% since the start of 2025. Next come Moderna (with their mRNA-4157 platform, though currently focused on melanoma, but the technology is the same) and the Chinese manufacturer behind iNeo-Vac-R01. These companies will get a "golden license" to print money, as a single dose of personalized vaccine costs between $80,000 and $150,000 per course on the market.
But vaccine manufacturers aren't the only winners. An unexpected surge awaits manufacturers of next-generation sequencers (like Illumina) and AI software for epitope prediction. Without their technologies, decoding a tumor genome in 4 weeks is impossible. Also in the plus column are insurance giants transitioning to premium "Oncology Precision" plans — they will raise premiums but reduce payouts for chemotherapy (since fewer patients will be on chemo).
Who loses? The generic chemotherapy market — gemcitabine and nab-paclitaxel (Abraxane). Their sales volume in first-line PDAC therapy will plummet by 40-50% within 18 months once regulators approve vaccines as standard. Additionally, manufacturers of implantable port systems (for long-term chemo infusion) will feel the decline. And, of course, clinics that haven't invested in personalized medicine labs lose out. Treating pancreatic cancer "the old way" will become economically unviable — patients with money will simply go to vaccination centers.
However, it's not all rosy. Also losing out are ordinary taxpayers in free healthcare systems (like the NHS in Britain or compulsory health insurance in Russia). The cost of treating one patient with the vaccine exceeds $100,000, plus support costs. That's 15-20 times more expensive than a course of chemotherapy. Consequently, access to the "cancer vaccine" will be strictly segmented by income for the next 5 years, creating an ethical chasm.
What the Media Aren't Saying
The biggest omission I hear on every insider webinar is: the vaccine does not treat macro-metastases. All those 19-month survival figures result from starting vaccination either after removal of the primary tumor (adjuvant setting) or with a low volume of metastatic disease. If a patient already has a huge tumor in the tail of the pancreas with ascites, vaccination will likely cause a fatal cytokine storm (exacerbated inflammation that kills faster than the cancer) or simply won't work in time. The iNeo-Vac-R01 trials included patients with ECOG 1 (practically healthy, active), not bedridden patients. The media create the illusion that a "shot" will save the hopeless, but that's not true.
The second unspoken issue is the HLA (human leukocyte antigen) problem. Most neoantigen selection algorithms are tuned to common HLA genotypes (Caucasian or Asian races). For people with rare haplotypes, finding suitable peptides is difficult or even impossible. The Chinese study worked brilliantly on its population. But in multicultural US or Europe, the percentage of non-responders for technical reasons (lack of suitable targets) could be higher than the official 50%.
And the third, most frightening for the pharma market — production time. 9 weeks from biopsy to injection is the dream limit for 2025. But for pancreatic cancer, 9 weeks is an eternity. Half of patients with advanced disease simply don't survive to receive their vaccine dose. While the company makes the mRNA, the tumor progresses. That's why all successful cases are patients who have already undergone resection (tumor removed, time available). For truly metastatic cancer (stage IV), the vaccine is still a palliative fantasy, not a real chance.
Forecast: Next 30 Days and 90 Days
In 30 days (by mid-June 2026): The first public FDA hearings for accelerated registration (Regenerative Medicine Advanced Therapy designation) for autogene cevumeran will begin. We expect the release of the official protocol for the global phase III study IMCODE 003. This will trigger a new wave of hype and a further 5-7% rise in BioNTech stock. However, like a shadow, a retrospective analysis of Chinese data will follow, revealing that out of 13 enrolled patients, 3 dropped out due to progression before receiving the second dose — this data will make investors nervous, and we'll see a market correction.
Also within 30 days, expect statements from Merck and Moderna. They will try to "catch up" with competitors by announcing their own data on KRAS-specific vaccines. It's highly likely they will announce the start of a combined "Prime-Pull" protocol (amphiphile prime + mRNA booster) to circumvent BioNTech's patents. This will heat up interest in small biotechs like Evaxion and Geneos Therapeutics.
In 90 days (by August 2026): Reality will intervene in the euphoria. Clinics will begin reporting the first cases of "hyperprogression" — paradoxical acceleration of tumor growth after vaccination. In the subgroup of patients with TP53 gene mutations, this may occur in 5-7% of cases due to T-cell exhaustion. This doesn't negate the success for the 50% who respond, but it will create a narrative that "the vaccine is dangerous," and regulators may require expanded warnings on packaging. Additionally, by August, the market will realize the logistics problem: manufacturing capacity for mRNA synthesis for oncology is limited, and a shortage will occur, driving the cost per course up to €180,000.
Finally, the main forecast: within 90 days, one of the major US insurance companies (e.g., UnitedHealthcare) will issue a coverage protocol for personalized vaccines ONLY if chemotherapy is ineffective. This will be a cold shower for developers — instead of replacing chemo, the vaccine will become a "last resort." The market will correct by 15-20%, weeding out speculators, leaving only those who truly understand the biology. It is now, not at the moment of hype, that real investors are going long on BioNTech and China's CStone Pharmaceuticals, knowing that in 3 years vaccination will become the standard of adjuvant therapy for PDAC. Everything else is just words.
— Editorial Team
